NeuroVive Pharmaceutical AB Interim report January – March 2018
Successful rights issue
Press releases
NeuroVive and Yungjin reports positive KL1333 phase I clinical study results paving the way for further clinical development
Lund, Sweden and Seoul, Korea, 21 May 2018 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly an ...
Amendment: Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
Lund, Sweden, 27 April 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) (“NeuroVive”) today on 27 April 2018 held its Annual General Meeting (AGM). A summary of the resolutions ...
Preferential rights issue in NeuroVive oversubscribed
THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR IN ANY OTHER JURISDICTION W ...
NeuroVive’s Board Members, Senior Executives and employees will subscribe units in the ongoing rights issue
In the current rights issue in NeuroVive, the Board, Senior Executives and employees have undertaken to subscribe for at least 191,200 units equivalent to MSEK 1.5. The subscription period in [&hellip ...
NeuroVive’s KL1333 receives FDA Orphan Drug Designation for treatment of mitochondrial diseases
Lund, Sweden, 18 April 2018 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has been granted Orphan Drug Designation by t ...
NeuroVive publishes prospectus in connection with preferential rights issue
THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF ...
NeuroVive Pharmaceutical AB publishes 2017 Annual report
Lund, Sweden, 26 March, 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2017 is now available on the company's ...
NeuroVive decides on a Rights issue for continued drug development
Lund, Sweden, 15 February 2018, NeuroVive Pharmaceutical AB (publ) (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announces that the Board of Directors of NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or "th ...
NeuroVive reports breakthrough in mitochondrial myopathy project
Lund, Sweden, 29 January 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a breakthrough in the company's project NVP025 for developing treatment of mitochondria ...
NeuroVive’s KL1333 program granted orphan drug designation by the European Commission
Lund, Sweden, 13 December 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), announced today that the European Commission has granted orphan drug designation (ODD) for the compa ...
NeuroVive reports promising progress in its clinical project for genetic mitochondrial diseases, KL1333
Lund, Sweden, 11 December 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm today announced that the phase I clinical study in Korea within the companies' join ...